about
Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives.Safety and efficacy evaluation of albumin-bound paclitaxel.Amatuximab and novel agents targeting mesothelin for solid tumors.Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance.Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.An historical overview over PharmacovigilanceEU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodiesPharmacovigilance workflow in Europe and Italy and pharmacovigilance terminologyPharmacovigilance in oncologyTargeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilanceAn Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative ReviewSafety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer DrugsSafety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid CancerSafety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous MelanomaSafety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung CancerPharmacovigilance of anti-cancer medicines: opportunities and challenges
P50
Q35183601-D9B20C2E-B9C5-4E65-8E7D-67D404BC48F1Q36798913-54F92E82-DC9B-4570-8E35-BBDC8B7CFD0CQ38190090-94497B69-7A92-436C-8357-FD014CBED783Q47126660-65535A36-5DF9-4C27-9194-7C898DBFCD73Q48985530-9BD77678-31E0-4459-B754-EC6D96EFEEB3Q51034561-DF0F1372-9A4E-403B-9340-0C9275EB5D30Q57172382-52672EA8-FEB5-452A-B4F6-5DA4DC0C8144Q58792200-30644796-1253-4A53-B428-41C631AAE760Q58792204-CD6C2D2B-DF4A-4363-A5D3-4CFCD3C8EFC6Q58804356-BA704B44-D0DD-4649-8A9B-4DC27F294F38Q88766822-83D73B93-9122-46AE-B238-4BF2257F3812Q91460249-F8259335-8D51-4079-825E-DDFF1386524FQ91505085-FB9E3DCC-5D69-488F-8EB8-FFF68AC64A59Q92292313-03EC5780-3CC4-4D8A-816B-23A1741C5DB8Q92292318-35D80B24-46C9-4FEE-8512-D2BDCC02D661Q92292327-EC65FF77-D74D-4F83-8555-686D40EA8AA7Q96581984-C5633E26-FE7A-426C-82DB-3490A324CF60
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Baldo
@ast
Paolo Baldo
@en
Paolo Baldo
@es
Paolo Baldo
@nl
Paolo Baldo
@sl
type
label
Paolo Baldo
@ast
Paolo Baldo
@en
Paolo Baldo
@es
Paolo Baldo
@nl
Paolo Baldo
@sl
prefLabel
Paolo Baldo
@ast
Paolo Baldo
@en
Paolo Baldo
@es
Paolo Baldo
@nl
Paolo Baldo
@sl
P106
P21
P31
P496
0000-0002-5106-7120